trending Market Intelligence /marketintelligence/en/news-insights/trending/VjfxST9Go7A139SbnWn_SQ2 content esgSubNav
In This List

Pfizer acquires AstraZeneca's antibiotics business

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Pfizer acquires AstraZeneca's antibiotics business

Pfizer Inc. acquired AstraZeneca PLC's late-stage antibiotics business for an upfront payment of $550 million.

AstraZeneca will receive another $175 million in January 2019 and is eligible for $250 million in commercial, manufacturing and regulatory milestones.

Pfizer will also pay up to $600 million in sales-related payments as well as recurring, double-digit royalties on sales of Zavicefta and ATM-AVI in certain markets.